EGFR and non-small cell lung carcinoma: This analysis is crucial for informing clinical decisions when selecting the optimal therapy for T790M‐negative patients with EGFR‐mutated advanced NSCLC after first‐ or second‐generation EGFR‐TKIs treatments.